LatestData & Analysis

I Stock 539359546
Data & Analysis

CVCA H1 2017 Quarterly Exclusive: PE Market Bounces Back

PE

This article is part of a new series, CVCA Quarterly Exclusive, written and published by the Canadian Venture Capital and Private Equity Association. This series provides an analysis of the CVCA’s most recently published VC & PE Canadian Market Overview through expert commentary and perspectives. Compared to venture capital activity in Canada, private equity activity has more-or-less

I Stock 637229530
Data & Analysis

CVCA H1 Quarterly Exclusive: Top VC Deal Profile – Repare Therapeutics Inc.

VC

This article is part of a new series, CVCA Quarterly Exclusive, written and published by the Canadian Venture Capital and Private Equity Association. This series provides an analysis of the CVCA’s most recently published VC & PE Canadian Market Overview through expert commentary and perspectives. Versant Ventures Goes Behind-the-Scenes on the Second Largest VC Deal in H1

CVCA Data Vis VCPE Canada H12017 Final26
Data & Analysis

CVCA H1 2017 Quarterly Exclusive: Rebound Year For PE Exits

PE

This article is part of a new series, CVCA Quarterly Exclusive, written and published by the Canadian Venture Capital and Private Equity Association. This series provides an analysis of the CVCA’s most recently published VC & PE Canadian Market Overview through expert commentary and perspectives. The recently released H1 2017 VC & PE Canadian Market Overview noted

CVCA Data Vis VCPE Canada H12017 Final14
Data & Analysis

CVCA H1 2017 Quarterly Exclusive: Behind the Robust Return of VC Exits

VC

This article is part of a new series, CVCA Quarterly Exclusive, written and published by the Canadian Venture Capital and Private Equity Association. This series provides an analysis of the CVCA’s most recently published VC & PE Canadian Market Overview through expert commentary and perspectives. Last year was undoubtedly a huge year for venture capital investment activity

I Stock 701117612
Data & Analysis

VC Investing: The Convergence of AI and Healthcare

VC

Quark Venture’s Partner & CEO weighs in on the future of AI and its role in the healthcare vertical There’s been plenty of media coverage lately about artificial intelligence. Most reporting has been generated through the vastly different views of people like Elon Musk the CEO of Tesla, SpaceX, and Neuralink, and Mark Zuckerberg, the

Psychology of a Deal 680x365px
Data & Analysis

Private Equity Deal Making: The Psychology Behind the Deal

PE

There’s no question there are certain predictors in any deal making process that can either enhance or erode the success of a deal. Generally speaking, that’s why the due diligence process is key—both for investors as well as the portfolio companies that they’re acquiring or investing in. And while the due diligence process is largely

I Stock 514851042
Data & Analysis

Canadian Agribusiness continues to gain momentum in Q1

VC

Although not as flush as the first quarter last year, the Canadian venture capital industry is still looking strong. Based on final Q1 2017 CVCA data (Q2 2017 final data scheduled to be released on August 23rd), $905M was disbursed over 98 deals in the first quarter. This compares to $956M over 128 deals from

Real Matters TSX CREDIT
Data & Analysis

Behind the Scenes with the Investors: The Real Matters IPO

VC

Photo Credit: Carey Diamond A month after announcing its intention to go public, Markham Ontario-based Real Matters Inc. (TSX: REAL) has begun trading, raising C$156 million with common shares at C$13.00 per share, giving the company a valuation in excess of C$1 billion. The Real Matters IPO marks an end to a two-year dry spell for

I Stock 510970768
Data & Analysis

Calculating the Competency of Management: The Investor’s View

VC

Evaluating an investment involves complex research. According to early-stage micro seed investment fund and mentoring program, Seedcamp, determining the value of an investment consists of market forces of the industry and sector of the company, the balance between the demand and supply of money, the frequency and size of latest exits and a stack of other quantitative

I Stock 517743436
Data & Analysis

Venture Capital‑backed Zymeworks Goes Public

VC

Vancouver-based Zymeworks (TSE/NYSE: ZYME) debuted on the public markets last Friday, just two weeks after announcing its intention to go public. The company raised CAD $79.7 million in the IPO from the sale of 4.5 million common shares at CAD $17 per share. Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and